When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ABBV - Revance's DAXI shows positive effect in frown line studies
AbbVie Inc.
Revance Therapeutics (NASDAQ:RVNC) announces positive results from two open-label dose-escalating Phase 2a clinical trials evaluating DaxibotulinumtoxinA (DAXI) for the treatment of dynamic forehead lines following glabellar (frown) line injections and lateral canthal lines (crow’s feet).
More news on: Revance Therapeutics, Inc., AbbVie Inc., Evolus, Inc., Healthcare stocks news,